CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma Apr 8 Written by Team Rxtrospect Schedule Demo Team Rxtrospect Previous Previous FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer Next Next FDA grants tumor agnostic accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors
CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma Apr 8 Written by Team Rxtrospect Schedule Demo Team Rxtrospect
